Ceftriaxone as a single agent in empirical therapy of unexplained fever in granulocytopenic children with solid tumors

Journal of Chemotherapy

Volumn 9, Issue 3, 1997, Pages 227-231

  Bartolozzi, S ^a   Clerico, A ^a   Properzi, E ^a   Minori, A ^a   Castello, M A ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Ceftriaxone; Empiric antibiotic monotherapy; Febrile neutropenia; Neutropenic children; Solid tumors

Indexed keywords

CEFTAZIDIME; CEFTRIAXONE;

ACUTE LEUKEMIA; ADOLESCENT; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; CHILD; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKOCYTE COUNT; MALE; MINIMUM INHIBITORY CONCENTRATION; PYREXIA IDIOPATHICA; SOLID TUMOR;

EID: 0030789386     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1997.9.3.227     Document Type: Article

References (14)

1. Bodey GP. Infection in cancer patients. A continuing association. Am J Med 1986; 81 (Suppl. A): 11-26.
2. Klastersky J. Empirical therapy for bacterial infections in granulocytopenic patients. Support Care Cancer 1994; 2: 161-168.
3. Dejace P, Klastersky J. Comparative review of combination therapy: two beta-lactams versus beta-lactam plus aminoglycoside. Am J Med 1986; 80 (Suppl. B): 29-38.
4. Rolston KVI, Jones PG, Fainstein V, Elting L, Bodey GP. Ceftizoxime plus ticarcillin: double beta-lactam therapy for infections in cancer patients. J Antimicrob Chemother 1987; 19: 367-371.
5. Rolston KVI, Bolivar R, Fainstein V, Jones PG, Elting L, Bodey GP. Cefotaxime: single agent therapy for infections in cancer patients with adequate granulocyte counts. J Antimicrob Chemother 1985; 15: 91-96.
6. Oturai PS, Hollander NH, Hansen OP, et al. Ceftriaxone versus latamoxef in febrile granulocytopenic patients: empirical monotherapy in patients with solid tumors. Eur J Cancer 1993; 9: 1274-1279.
7. Merry TL, Curtis H, Howden R, Lilleyman JS. Ceftriaxone as a single agent in empirical therapy of fever in children with agranulocytosis. Insights Treat Serious Infect 1988; 1: 93-95.
8. Liang R, Yung R, Chiu E et al. Ceftazidime versus imipenem-cilastin as initial monotherapy for febrile granulocytopenic patients. Antimicrob Agents Chemother 1990; 34: 1336-1341.
9. Klastersky J. Febrile neutropenia: focus on antibacterial therapy. Gardiner-Caldwell Communications Eds. UK 1992: 24-25.
10. Washington JA, Jones RN, Gerlach EII, Murrey PR, Allen SD, Knapp CC. Multicenter comparison of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime. Antimicrob Agents Chemother 1993; 37: 1696-1700.
11. EORTC International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trial Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 951-958.
12. EORTC International Antimicrobial Therapy Cooperative Group. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584-93.
13. Wade SC, Schimpff SC, Newman KA et al. Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med 1987; 97: 503-8.
14. Pizzo PA. Management of fever in patients with cancer and treatment induced neutropenia. N Engl J Med 1993; 328: 1323-32.